KOSDAQBiotech & Pharma246710

T&R Biofab

₩1,682▼ 2.21%2026-11-18 close
Market Cap
₩80.2B
Turnover
₩500M
Volume
280K
Shares out.
47.7M
PER
—
PBR
4.2×
EPS
-₩430
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales Surge and a Q3 Profit Turn, Balance-Sheet Strain Remains

T&R Biofab's sales rose to KRW 27 billion in 2025 and its operating profit turned positive in the third quarter of 2026 at KRW 136 million, but a debt-to-equity ratio of 255.6% at end-2025 and KRW 23.6 billion in combined net losses attributable to controlling shareholders over the four most recent quarters remain balance-sheet burdens.

  1. 1

    Sales in 2025 rose 453.3% year on year to KRW 27 billion. Cosmetics sales, which did not exist until 2024, exceeded KRW 12 billion in 2025 and drove the increase through the cosmetics subsidiary.

  2. 2

    Operating profit in the third quarter of 2026 was KRW 136 million, a turn to profit from the prior-year quarter. Net loss attributable to controlling shareholders was KRW 1.52 billion in the same quarter, while the four-quarter total stands at KRW 23.6 billion.

  3. 3

    The company said it obtained U.S. FDA 510(k) clearance for its skull reconstruction implant in August 2026. It is now widening distribution in the United States, Latin America and Southeast Asia, including at MEDICA 2026 in Düsseldorf.

  4. 4

    The debt-to-equity ratio was 255.6% at end-2025, with total liabilities of KRW 66.6 billion against total equity of KRW 26.1 billion. Operating cash flow was negative in each year from 2022 to 2025.

  5. 5

    Provisional consolidated sales for the first half of 2026 were KRW 18.3 billion, up 46% year on year, and the cosmetics subsidiary accounted for KRW 11.8 billion of that provisional total. Consolidated growth therefore leans heavily on the subsidiary.

02

Business structure

T&R Biofab is a KOSDAQ-listed company that develops regenerative medical products and surgical devices using 3D bioprinting.

Its core line is bioabsorbable scaffolds made from polycaprolactone (PCL) and beta-tricalcium phosphate (β-TCP), including a skull reconstruction implant (CI), the TnR Mesh for orbital fracture repair and patient-specific implants (PSI).

The company says these products are supplied to more than 200 hospitals and clinics in Korea and have been applied in over 100,000 clinical cases.

The second pillar is extracellular matrix (ECM)-based biosurgical solutions, including the powder-type composite hemostat Hemofix, the wound dressing Reprofoam and an acellular xenogeneic dermal matrix (ADM) line.

Standalone sales from this business reached KRW 3.7 billion in the second quarter of 2026, up 125% year on year. The third pillar is a freeze-dried ball cosmetics business run by a wholly owned subsidiary, which uses ODM and OEM capabilities and a monthly capacity of about 4 million balls.

That subsidiary reported provisional first-half 2026 sales of KRW 11.8 billion, up 25%. Standalone sales were KRW 3.07 billion in the third quarter of 2026, up 40.7%, against consolidated sales of KRW 8.89 billion, which shows how much of the consolidated top line depends on the subsidiary.

Overseas, the company is expanding supply with existing partners in Colombia, Russia, Mexico, Taiwan, Venezuela and Argentina, and is reviewing new deals with device makers in Germany, Japan, Hong Kong and the United States.

In organ engineering, it has presented a platform that assembles vascularized cell blocks with a team from Korea Polytechnic University, and its organoid clinical trial services generate revenue on a small scale. Overall, the medical device core and the cosmetics subsidiary together drive sales.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩7B-₩1.3B−18.2%
2025Q4₩7.5B-₩2.3B−30.5%
2026Q1₩8.7B-₩900M−10.7%
2026Q2₩9.5B-₩900M−9.7%
2026Q3₩8.9B₩100M1.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩5.8B-₩12.9B-₩10.3B−224.1%−26.3%93.4%
2023₩5.2B-₩12.7B-₩13.4B−244.7%−43.0%220.0%
2024₩4.9B-₩13.3B-₩7.7B−272.9%−31.7%306.6%
2025₩27B-₩9.1B-₩32B−33.6%−122.6%255.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual sales were KRW 5.75 billion in 2022, KRW 5.2 billion in 2023 (down 9.7% year on year) and KRW 4.87 billion in 2024 (down 6.3%), before jumping to KRW 27 billion in 2025 (up 453.3%). Among 2022 to 2025, 2025 was the largest year and 2024 the smallest.

Cosmetics sales, which did not exist until 2024, exceeded KRW 12 billion in 2025 and drove the increase, according to the company.

Operating losses were KRW 12.9 billion in 2022, KRW 12.7 billion in 2023, KRW 13.3 billion in 2024 and KRW 9.05 billion in 2025, and the operating margin moved from -224.1% in 2022 to -33.6% in 2025.

Net loss attributable to controlling shareholders was KRW 10.3 billion in 2022, KRW 13.4 billion in 2023 (loss widened year on year), KRW 7.68 billion in 2024 (loss narrowed) and KRW 32 billion in 2025 (loss widened).

In 2025 the net loss was far larger than the operating loss, and the net loss including non-controlling interests was the same KRW 32 billion. The debt-to-equity ratio rose from 93.4% in 2022 to 220.0% in 2023 and 306.6% in 2024 before easing to 255.6% in 2025.

At end-2025 total equity was KRW 26.1 billion, all of it attributable to controlling shareholders, against total liabilities of KRW 66.6 billion. Operating cash flow was -KRW 5.89 billion in 2022, -KRW 6.96 billion in 2023, -KRW 11.7 billion in 2024 and -KRW 7.47 billion in 2025, negative in every year.

Quarterly sales rose from KRW 6.95 billion in Q3 2025 to KRW 7.52 billion in Q4 2025 (up 8.2% quarter on quarter), KRW 8.72 billion in Q1 2026 (up 16.0%) and KRW 9.54 billion in Q2 2026 (up 9.3%). Q3 2026 sales of KRW 8.89 billion fell 6.7% from the prior quarter but rose 27.9% from a year earlier.

Operating results moved from an operating loss of KRW 1.26 billion in Q3 2025 and KRW 2.29 billion in Q4 2025 to losses of KRW 931 million in Q1 2026 and KRW 928 million in Q2 2026, and then to an operating profit of KRW 136 million in Q3 2026.

The company attributed the profit turn to economies of scale from mass production of freeze-dried ball cosmetics and to lower losses in the production process. Cost of sales as a share of revenue was 61.7% in the quarter, below the prior-year level.

Net loss attributable to controlling shareholders narrowed to KRW 1.52 billion in Q3 2026, but the four-quarter total from Q4 2025 to Q3 2026 is KRW 23.6 billion. Cumulative sales for January to September 2026 were KRW 27.17 billion, up 39.7%, according to the provisional disclosure of October 19, 2026.

05

Industry analysis

The company operates in 3D bioprinted scaffolds and ECM-based biosurgical products, where device clearances and country-by-country approvals set the pace of product expansion, a different structure from drug development. The company has chosen to expand abroad from a base of domestic supply records, and its U.S.

FDA 510(k)-cleared skull reconstruction implant is the starting point. It names the United States, Latin America and Southeast Asia as strategic markets, and says Latin America and Southeast Asia are comparatively easier to enter.

MEDICA 2026, held in Düsseldorf from November 16 to 19, 2026 and billed as the world's largest medical device fair, is the venue for this push. Demand for devices originates with hospitals and distribution networks, so new customer wins depend on whether local distribution partners sign.

Unlike listed biopharma peers that rely on biosimilars, contract manufacturing or technology licensing, this company's earnings are led by its device and cosmetics subsidiary sales.

In hemostats and wound dressings it competes with domestic and foreign device makers, and it presents its patented EER (Excellent ECM Retention) technology as a point of differentiation. Organ and organoid work is discussed as a technology platform but contributes little to revenue so far.

The industry cycle position is hard to call on the current data, and building distribution after the U.S. clearance is the next variable.

06

Outlook

The nearest checkpoint the company has set is revenue from the United States. A company official said it aims to secure visible U.S. sales in the first half of 2027 on the back of the FDA clearance. In the same vein, it plans to develop Latin America and Southeast Asia as strategic markets for early export expansion.

During MEDICA 2026 it planned to discuss expanded supply with existing partners in Colombia, Russia, Mexico, Taiwan, Venezuela and Argentina, and it is reviewing possible new deals with device makers in Germany, Japan, Hong Kong and the United States.

On products, the ECM-based band-type wound dressing BONOFOAM is scheduled for a new launch in early 2027, which makes the wound dressing line a variable for 2027 results. The company has also said it is reviewing additional approvals for individual products.

Its cosmetics subsidiary said in July 2026 that repeat orders from existing customers and new product orders continue, which could support sales in the second half.

Consolidated operating profit turned positive in the third quarter of 2026, and whether that profitability continues after the fourth quarter is the next checkpoint. Full-year operating margin and operating cash flow will be confirmed in the 2026 annual report.

Taken together, the timing of U.S. sales, the BONOFOAM launch and continued subsidiary orders are the factors that will shape future results.

07

Valuation

PER
—
PBR
4.2×
ROE
-151.4%
EPS
-₩430
BPS
₩415
Dividend per share
₩0

Valuation has to be read against loss-making results. Because the company posted net losses over the four most recent quarters, its price-to-earnings ratio cannot be calculated and the share price cannot be compared with earnings.

The price-to-book ratio, by contrast, sits in a range with a large premium to net asset value.

That level can be read as the market pricing in FDA clearance, overseas sales expansion and subsidiary growth, but whether those expectations are realized can only be judged once the 2026 annual report and U.S. sales are confirmed.

Total liabilities of KRW 66.6 billion against total equity of KRW 26.1 billion is a factor to weigh in any comparison against net assets. The company does not pay dividends, so a dividend-based comparison does not apply.

The third quarter of 2026 was a profit on a single-quarter basis, so earnings-based comparison becomes meaningful only after more full-year results accumulate.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Q3 2026 operating profit turn

Operating profit in Q3 2026 was KRW 136 million, a turn to profit from a year earlier. The company attributed the change to economies of scale in mass producing freeze-dried ball cosmetics and to lower production losses. It also said the cost of sales ratio of 61.7% reflected the improved cost structure. Because the profit so far covers a single quarter, the fourth quarter onward is the next checkpoint.

U.S. FDA clearance and wider overseas reach

The company said its skull reconstruction implant (CI) received U.S. FDA 510(k) clearance in August 2026. At MEDICA 2026 it is reviewing possible new deals with U.S. device makers. It targets visible U.S. sales in the first half of 2027. Supply expansion through partners in Latin America and Southeast Asia is proceeding in parallel.

Subsidiary growth and wider ECM product lines

Blispack's provisional first-half 2026 sales were KRW 11.8 billion, up 25% from a year earlier. Standalone sales in the second quarter of 2026 reached KRW 3.7 billion, up 125% year on year. Growing sales of the hemostat Hemofix, the wound dressing Reprofoam and the ADM line led the biosurgical growth. The band-type wound dressing BONOFOAM is also scheduled for launch in early 2027.

09

Bear factors

Net losses over the last four quarters

Net loss attributable to controlling shareholders was KRW 16.6 billion in Q4 2025 and KRW 3.78 billion in Q2 2026, and the four-quarter total reaches KRW 23.6 billion. The 2025 loss of KRW 32 billion was larger than the KRW 7.68 billion of 2024.

Even in Q3 2026, when operating profit turned positive, a controlling-shareholder net loss of KRW 1.52 billion remained. The company has posted losses in each of the five quarters from Q3 2025 to Q3 2026.

Balance sheet and cash outflow

Total liabilities are well above total equity, so debt is far larger than capital. Operating cash flow was negative every year from 2022 to 2025, at -KRW 7.47 billion in 2025. Whether the profit turn halts cash outflows will show up only in full-year results. Changes in the financial burden can be checked in the 2026 annual report.

Subsidiary dependence and provisional figures

Of provisional first-half 2026 consolidated sales of KRW 18.3 billion, KRW 11.8 billion came from the cosmetics subsidiary, which is more than half. Repeat and new orders in cosmetics therefore largely shape consolidated results.

The provisional third-quarter sales disclosed on October 19, 2026 were KRW 8.91 billion, and the later disclosure showed KRW 8.89 billion. The company has said provisional results may differ from final figures.

10

Risk factors

Financial structure and funding

The debt-to-equity ratio fell from 306.6% in 2024 to 255.6% in 2025 but remains high. Operating cash flow was negative in all four years from 2022 to 2025, so operations have depended on outside funding.

A securities firm noted in a December 2025 report that a recent rights offering had stabilized the capital structure. If further funding is needed, dilution could follow.

Approval and overseas sales uncertainty

The company has FDA clearance, but U.S. sales are not yet realized and are targeted for the first half of 2027. Supply expansion with partners in Latin America and Southeast Asia, and new deals with makers in Germany, Japan, Hong Kong and the United States, are at the discussion stage.

Additional product approvals are also under review. If overseas channels do not open on schedule, the growth scenario could be delayed.

Reliance on the cosmetics subsidiary

Cosmetics sales at the subsidiary exceeded KRW 12 billion in 2025 and lifted consolidated sales. If the medical device core does not grow its share, changes in cosmetics demand pass straight through to consolidated results.

Standalone sales of KRW 3.07 billion in Q3 2026 were far below consolidated sales of KRW 8.89 billion. If subsidiary orders fall or the cost gains reverse, the profit trend could weaken.

11

What to watch next

  1. Through November 19, 2026

    Whether supply expansion talks with existing overseas partners and new-deal reviews with makers in Germany, Japan, Hong Kong and the United States produce outcomes. These would be the first signals of wider U.S., Latin American and Southeast Asian reach.

  2. Early 2027

    Whether the band-type wound dressing BONOFOAM launches as scheduled. This shows how much the wound dressing line adds to biosurgical sales.

  3. First half of 2027

    Whether U.S. sales of the FDA-cleared skull reconstruction implant become visible. This is the point to compare the company's stated target with actual sales.

  4. By end-March 2027

    The 2026 annual report confirms full-year sales, operating margin, operating cash flow and the debt-to-equity ratio. Whether the profit turn held through the fourth quarter becomes visible on an annual basis here.

12

Overall view

T&R Biofab's sales rose sharply to KRW 27 billion in 2025, and its operating profit turned positive in the third quarter of 2026.

Growth, however, leans on the cosmetics subsidiary and the ECM-based biosurgical lines, while the contribution from its 3D-printed implants depends on building distribution after U.S. clearance.

On the financial side, the debt-to-equity ratio was 255.6% at end-2025, operating cash flow was negative in every year from 2022 to 2025, and net losses attributable to controlling shareholders total KRW 23.6 billion over the four most recent quarters.

The share price sits in a range with a large premium to net assets, so how far future earnings expectations are realized is central to the assessment. Bullish factors include the FDA clearance, new deal reviews after MEDICA 2026, the planned BONOFOAM launch and repeat cosmetics orders.

Bearish factors include the wider 2025 net loss of KRW 32 billion attributable to controlling shareholders, dependence on the subsidiary, and the possibility that provisional figures differ from final ones.

The next checkpoints are the operating margin and cash flow in the 2026 annual report, U.S. sales in the first half of 2027, and the BONOFOAM launch in early 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. thevc.kr
  2. innoforest.co.kr
  3. kormedi.com
  4. bbn.kiwoom.com
  5. newstap.co.kr
  6. biotimes.co.kr
  7. tnrbiofab.com
  8. bioin.or.kr
  9. newstown.co.kr
  10. vegannews.co.kr
  11. alphabiz.co.kr
  12. rapportian.com
  13. v.daum.net
  14. m.news.nate.com
  15. rapportian.com
  16. v.daum.net
  17. mt.co.kr
  18. mt.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis